Comparative Effectiveness of Kyphoplasty and Radiation with or Without Radiofrequency Ablation in Spinal Metastases from Lung Cancer

<b>Background/Objectives:</b> Spinal metastases from lung cancer cause substantial pain, instability, and neurologic compromise. Radiotherapy and kyphoplasty are standard treatment modalities, while radiofrequency ablation (RFA) has emerged as a potential adjunct for cytoreduction. The objective of this study was to evaluate whether RFA confers additional benefit when combined with kyphoplasty and radiotherapy in patients with lung cancer spinal metastases. <b>Methods:</b> We conducted a retrospective cohort study of adults with lung cancer and spinal metastases from 2012-2024 using the TriNetX database. Patients were identified using International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes and stratified into two groups: kyphoplasty with radiotherapy alone versus kyphoplasty with radiotherapy and RFA. Propensity score matching was applied to balance demographic and clinical covariates. The primary outcome was 1-year all-cause mortality. Secondary outcomes included tumor recurrence, neurologic complications, and pain burden as assessed by opioid prescription rates. Risk ratios (RR) with 95% confidence intervals (CI) were calculated. <b>Results:</b> A total of 703 patients met inclusion criteria. After matching, no significant differences were observed between groups for 1-year mortality (RR 1.021, 95% CI 0.83-1.256), tumor recurrence (RR 0.989, 95% CI 0.789-1.238), neurologic complications (RR 1.052, 95% CI 0.563-1.967), or opioid use as a pain proxy (RR 0.986, 95% CI 0.76-1.28). <b>Conclusions:</b> The addition of RFA to kyphoplasty and radiotherapy did not significantly impact survival, recurrence, neurologic, or pain outcomes in patients with spinal metastases from lung cancer. These findings suggest that the incremental benefit of RFA in this setting is limited and emphasize the need for prospective studies to refine patient selection and treatment strategies.

Authors

Institutions

Publication Details

Journal
Healthcare
Published
2025-11-28
DOI
https://doi.org/10.3390/healthcare13233101
Primary Topic
Management of metastatic bone disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Effectiveness of Kyphoplasty and Radiation with or Without Radiofrequency Ablation in Spinal Metastases from Lung Cancer

Michael J. Karsy, Spencer Rasmussen, Kamal Shaik, Rudy J. Rahme et al.
Healthcare
Management of metastatic bone disease
article

Comparative Effectiveness of Kyphoplasty and Radiation with or Without Radiofrequency Ablation in Spinal Metastases from Lung Cancer

Michael J. Karsy, Spencer Rasmussen, Kamal Shaik, Rudy J. Rahme, Muhammad Hozien
article en

Abstract

<b>Background/Objectives:</b> Spinal metastases from lung cancer cause substantial pain, instability, and neurologic compromise. Radiotherapy and kyphoplasty are standard treatment modalities, while radiofrequency ablation (RFA) has emerged as a potential adjunct for cytoreduction. The objective of this study was to evaluate whether RFA confers additional benefit when combined with kyphoplasty and radiotherapy in patients with lung cancer spinal metastases. <b>Methods:</b> We conducted a retrospective cohort study of adults with lung cancer and spinal metastases from 2012-2024 using the TriNetX database. Patients were identified using International Classification of Disease, Tenth Revision, Clinical Modification (ICD-10-CM) codes and stratified into two groups: kyphoplasty with radiotherapy alone versus kyphoplasty with radiotherapy and RFA. Propensity score matching was applied to balance demographic and clinical covariates. The primary outcome was 1-year all-cause mortality. Secondary outcomes included tumor recurrence, neurologic complications, and pain burden as assessed by opioid prescription rates. Risk ratios (RR) with 95% confidence intervals (CI) were calculated. <b>Results:</b> A total of 703 patients met inclusion criteria. After matching, no significant differences were observed between groups for 1-year mortality (RR 1.021, 95% CI 0.83-1.256), tumor recurrence (RR 0.989, 95% CI 0.789-1.238), neurologic complications (RR 1.052, 95% CI 0.563-1.967), or opioid use as a pain proxy (RR 0.986, 95% CI 0.76-1.28). <b>Conclusions:</b> The addition of RFA to kyphoplasty and radiotherapy did not significantly impact survival, recurrence, neurologic, or pain outcomes in patients with spinal metastases from lung cancer. These findings suggest that the incremental benefit of RFA in this setting is limited and emphasize the need for prospective studies to refine patient selection and treatment strategies.

HealthcareVol. 13(23)
Neurosciences Institute (US), University of Michigan (US), Drexel University (US)
Openalex Percentile: Top 44%
Management of metastatic bone disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.